AngioDynamics（UG2）株式概要医療技術企業であるアンギオダイナミクス社は、米国内外で末梢血管疾患、腫瘍、外科治療に使用される医療機器、外科機器、診断機器の設計、製造、販売に従事している。 詳細UG2 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長3/6過去の実績0/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より42.5%で取引されている 収益は年間72.2%増加すると予測されています アナリストらは、株価が40.6%上昇するだろうとほぼ一致している。 リスク分析リスクチェックの結果、UG2 、リスクは検出されなかった。すべてのリスクチェックを見るUG2 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW496,135 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG496,135 investors already sharing narrativesYour Fair Value€Current Price€12.4036.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-184m414m2016201920222025202620282031Revenue US$413.8mEarnings US$54.8mAdvancedSet Fair ValueView all narrativesAngioDynamics, Inc. 競合他社StratecSymbol: XTRA:SBSMarket cap: €229.3mEckert & ZieglerSymbol: XTRA:EUZMarket cap: €877.9mDrägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.6bCarl Zeiss MeditecSymbol: XTRA:AFXMarket cap: €2.4b価格と性能株価の高値、安値、推移の概要AngioDynamics過去の株価現在の株価US$12.4052週高値US$13.2052週安値US$7.00ベータ0.341ヶ月の変化13.76%3ヶ月変化30.53%1年変化61.04%3年間の変化55.97%5年間の変化-43.64%IPOからの変化14.32%最新ニュースReported Earnings • Jul 15Full year 2026 earnings released: US$0.89 loss per share (vs US$0.83 loss in FY 2025)Full year 2026 results: US$0.89 loss per share (further deteriorated from US$0.83 loss in FY 2025). Revenue: US$320.2m (up 9.5% from FY 2025). Net loss: US$36.7m (loss widened 8.1% from FY 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 14AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2027AngioDynamics, Inc. provided earnings guidance for the Fiscal Year 2027. For the year, the Company expected net sales to be in the range of $336 million to $341 million.お知らせ • Jun 30AngioDynamics, Inc. to Report Q4, 2026 Results on Jul 14, 2026AngioDynamics, Inc. announced that they will report Q4, 2026 results at 9:30 AM, US Eastern Standard Time on Jul 14, 2026お知らせ • Jun 17AngioDynamics Receives FDA IDE Approval For RELIEF Feasibility Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment For Benign Prostatic HyperplasiaAngioDynamics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). BPH is among the most prevalent urologic conditions affecting men in the United States, with an estimated 15 million men exhibiting symptoms and more than 300,000 surgical procedures performed annually. BPH can cause lower urinary tract symptoms, including urinary frequency, urgency, weak stream, and incomplete bladder emptying, that impair daily function and quality of life. Current treatment options range from pharmacologic therapy to surgical interventions such as transurethral resection of the prostate (TURP) and newer minimally invasive procedures, underscoring the need for additional approaches that balance effectiveness with preservation of sexual and urinary function. The NanoKnife System is cleared for the surgical ablation of prostate tissue. In prior clinical experience with IRE in the prostate, physicians observed meaningful improvements in urinary symptoms associated with BPH in patients treated for intermediate-risk prostate disease, an observation that provided clinical rationale for the RELIEF study. The RELIEF study is a prospective, single-arm clinical study that will enroll 40 subjects at up to five clinical sites in the United States. Patients, at six months post-treatment, will be evaluated for the primary endpoints and will also be followed for a total of five years for secondary endpoints. The primary effectiveness endpoint is the mean change in International Prostate Symptom Score (IPSS) from baseline to six months post-procedure. The primary safety endpoint is the incidence and severity of device-related adverse events during that period. RELIEF will evaluate the preliminary safety and effectiveness of IRE delivered via the NanoKnife System for the relief of BPH-related symptoms. The results will establish the evidence foundation for future clinical development of IRE as a minimally invasive treatment option for BPH. The study incorporates validated, well-established endpoints such as IPSS, uroflowmetry, and quality-of-life measures, alongside careful monitoring of sexual function and long-term durability through five years of follow-up. In the RELIEF study, electrodes are placed transperineally into predefined treatment zones of the prostate under transrectal ultrasound guidance and general anesthesia. Treatment planning targets the transition zone bilaterally while preserving critical structures, including the neurovascular bundles, external sphincter, and urethra. The NanoKnife System delivers short pulses of electrical energy to create permanent nanopores in cell membranes, resulting in precise, non-thermal ablation of prostate tissue. The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. United States: The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. Canada: The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability. European Union: The NanoKnife System is indicated for the ablation of soft tissue and tumors of the pancreas, kidney, liver, or prostate, including intermediate risk prostate cancer. The NanoKnife System has not received clearance for the therapy or treatment of any specific disease or condition. The NanoKnife System when used for the treatment of benign prostate hyperplasia is an investigational device. Limited by United States law to investigational use.Breakeven Date Change • May 20No longer forecast to breakevenThe 4 analysts covering AngioDynamics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$700.0k in 2028. New consensus forecast suggests the company will make a loss of US$12.1m in 2028.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Karen Licitra was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.最新情報をもっと見るRecent updatesReported Earnings • Jul 15Full year 2026 earnings released: US$0.89 loss per share (vs US$0.83 loss in FY 2025)Full year 2026 results: US$0.89 loss per share (further deteriorated from US$0.83 loss in FY 2025). Revenue: US$320.2m (up 9.5% from FY 2025). Net loss: US$36.7m (loss widened 8.1% from FY 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 14AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2027AngioDynamics, Inc. provided earnings guidance for the Fiscal Year 2027. For the year, the Company expected net sales to be in the range of $336 million to $341 million.お知らせ • Jun 30AngioDynamics, Inc. to Report Q4, 2026 Results on Jul 14, 2026AngioDynamics, Inc. announced that they will report Q4, 2026 results at 9:30 AM, US Eastern Standard Time on Jul 14, 2026お知らせ • Jun 17AngioDynamics Receives FDA IDE Approval For RELIEF Feasibility Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment For Benign Prostatic HyperplasiaAngioDynamics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). BPH is among the most prevalent urologic conditions affecting men in the United States, with an estimated 15 million men exhibiting symptoms and more than 300,000 surgical procedures performed annually. BPH can cause lower urinary tract symptoms, including urinary frequency, urgency, weak stream, and incomplete bladder emptying, that impair daily function and quality of life. Current treatment options range from pharmacologic therapy to surgical interventions such as transurethral resection of the prostate (TURP) and newer minimally invasive procedures, underscoring the need for additional approaches that balance effectiveness with preservation of sexual and urinary function. The NanoKnife System is cleared for the surgical ablation of prostate tissue. In prior clinical experience with IRE in the prostate, physicians observed meaningful improvements in urinary symptoms associated with BPH in patients treated for intermediate-risk prostate disease, an observation that provided clinical rationale for the RELIEF study. The RELIEF study is a prospective, single-arm clinical study that will enroll 40 subjects at up to five clinical sites in the United States. Patients, at six months post-treatment, will be evaluated for the primary endpoints and will also be followed for a total of five years for secondary endpoints. The primary effectiveness endpoint is the mean change in International Prostate Symptom Score (IPSS) from baseline to six months post-procedure. The primary safety endpoint is the incidence and severity of device-related adverse events during that period. RELIEF will evaluate the preliminary safety and effectiveness of IRE delivered via the NanoKnife System for the relief of BPH-related symptoms. The results will establish the evidence foundation for future clinical development of IRE as a minimally invasive treatment option for BPH. The study incorporates validated, well-established endpoints such as IPSS, uroflowmetry, and quality-of-life measures, alongside careful monitoring of sexual function and long-term durability through five years of follow-up. In the RELIEF study, electrodes are placed transperineally into predefined treatment zones of the prostate under transrectal ultrasound guidance and general anesthesia. Treatment planning targets the transition zone bilaterally while preserving critical structures, including the neurovascular bundles, external sphincter, and urethra. The NanoKnife System delivers short pulses of electrical energy to create permanent nanopores in cell membranes, resulting in precise, non-thermal ablation of prostate tissue. The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. United States: The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. Canada: The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability. European Union: The NanoKnife System is indicated for the ablation of soft tissue and tumors of the pancreas, kidney, liver, or prostate, including intermediate risk prostate cancer. The NanoKnife System has not received clearance for the therapy or treatment of any specific disease or condition. The NanoKnife System when used for the treatment of benign prostate hyperplasia is an investigational device. Limited by United States law to investigational use.Breakeven Date Change • May 20No longer forecast to breakevenThe 4 analysts covering AngioDynamics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$700.0k in 2028. New consensus forecast suggests the company will make a loss of US$12.1m in 2028.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Karen Licitra was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 14AngioDynamics Announces Two-Year Preserve Trial Data Demonstrating Durable Nanoknife Ire System Outcomes In Intermediate-Risk Prostate CancerAngioDynamics, Inc. announced two-year results from the PRESERVE pivotal trial (NCT04972097) demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of intermediate-risk prostate cancer. The PRESERVE trial is a prospective, single-arm pivotal IDE study evaluating focal irreversible electroporation (IRE) using the NanoKnife System in 121 patients with Gleason Grade Group 2–3 intermediate-risk prostate cancer, conducted across 17 U.S. clinical centers in collaboration with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC). Primary 12-month results, published in European Urology in July 2025, demonstrated an 80% freedom-from-treatment-failure rate among protocol-biopsied patients. At 24 months, the updated findings confirm durability of outcomes: 94.4% of analysis-eligible patients (68 of 72) completed the 24-month assessment, reflecting strong cohort retention. No new treatment failures were identified among patients with available follow-up at 24 months. One patient (1.5%) underwent a clinically indicated biopsy, which was negative for any cancer. 97% of patients (66 of 68) had a PSA at 24 months below their baseline value. No new device- or procedure-related adverse events were reported between the 12- and 24-month assessments. The 24-month PRESERVE data complement an international long-term evidence base for focal IRE, including median five-year outcomes from a 2023 international multi-institutional cohort demonstrating sustained oncologic control and preservation of functional outcomes. PRESERVE Trial — 24-Month Results Summary: Focal IRE Ablation Using the NanoKnife System for Intermediate-Risk Prostate Cancer. Study Design: Parameter Detail. Trial Name PRESERVE (NCT04972097). Study Type Prospective, single-arm, pivotal IDE study. Technology NanoKnife System — Focal Irreversible Electroporation (IRE). Population Gleason Grade Group 2–3 (Gleason 3+4 or 4+3), clinical stage =T2c intermediate-risk prostate cancer. Sites 17 U.S. clinical centers. Partner Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC). Sponsor AngioDynamics, Inc. Key 24-Month Results: Endpoint Result. Total Enrolled 121 patients. 24-Month Analysis-Eligible 72 patients. 24-Month Completers 68 of 72 (94.4%). New Treatment Failures (12–24 mo) 0. Clinically Triggered Biopsies 1 (negative for any cancer). PSA Below Baseline at 24 Months 66 of 68 (97%). New Device/Procedure-Related AEs (12–24 mo) 0. 12-Month Primary Endpoint (Reference): Endpoint Result. Freedom from Treatment Failure 80% among protocol-biopsied patients. Publication European Urology, July 2025 (George et al.). With a growing body of prospective U.S. pivotal data and long-term international evidence supporting the safety and efficacy of focal IRE, the NanoKnife System continues to gain traction as a meaningful treatment option for men with intermediate-risk prostate cancer who seek durable oncologic control while preserving quality of life. AngioDynamics is advancing the NanoKnife IRE System evidence base and the reimbursement infrastructure needed to bring this option to more patients and physicians across care settings. The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. United States: The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. Canada: The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability. European Union: The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer.お知らせ • Apr 02Angiodynamics, Inc. Provides Earnings Guidance for Fiscal Year 2026AngioDynamics, Inc. provided earnings guidance for fiscal year 2026. For the period, the company expects net sales of $313.5 million to $315.5 Million compared to previous guidance of $312 million to $314 Million as of January 6, 2026.お知らせ • Mar 19AngioDynamics, Inc. to Report Q3, 2026 Results on Apr 02, 2026AngioDynamics, Inc. announced that they will report Q3, 2026 results Pre-Market on Apr 02, 2026お知らせ • Jan 06+ 2 more updatesJim Clemmer Intends to Retire as President of AngioDynamics, Inc. During Fiscal year 2027AngioDynamics, Inc. announced that Jim Clemmer to retire during fiscal year 2027 as President and CEO upon appointment of successor; Board initiates comprehensive CEO search. The Company also announced that Mr. Clemmer has informed the Board of Directors of his intention to retire from the Company upon the appointment of a successor, which is anticipated to occur during fiscal 2027. The Board has established a search committee to conduct a comprehensive search, which will be assisted by a leading executive search firm, to identify the Company’s next CEO. Until his successor is appointed, Mr. Clemmer will continue as President and CEO, leading and overseeing the Company’s strategic and financial initiatives with a focus on revenue growth and profitability.お知らせ • Dec 23AngioDynamics, Inc. to Report Q2, 2026 Results on Jan 06, 2026AngioDynamics, Inc. announced that they will report Q2, 2026 results Pre-Market on Jan 06, 2026お知らせ • Oct 02AngioDynamics, Inc. Revises Earnings Guidance for the Full Fiscal Year 2026AngioDynamics, Inc. revised earnings guidance for the full fiscal year 2026. For the year, the company expects net sales to be between $308 million to $313 million against previous guidance of between $305 million to $310 million.お知らせ • Sep 27AngioDynamics, Inc., Annual General Meeting, Nov 10, 2025AngioDynamics, Inc., Annual General Meeting, Nov 10, 2025.お知らせ • Sep 18AngioDynamics, Inc. to Report Q1, 2026 Results on Oct 02, 2025AngioDynamics, Inc. announced that they will report Q1, 2026 results Pre-Market on Oct 02, 2025お知らせ • Jul 29Angiodynamics, Inc. Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb IschemiaAngioDynamics, Inc. announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee (AMBITION BTK). AMBITION BTK is a prospective, multicenter, randomized controlled trial (RCT) designed to investigate the clinical safety and effectiveness of the Auryon Athe rectomy System combined with standard balloon angioplasty, compared to balloon angioplasty alone, in treating infrapopliteal lesions in patients with Critical Limb IschemIA (CLI).お知らせ • Jul 15AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2026AngioDynamics, Inc. provided earnings guidance for the Fiscal Year 2026. For the year, the Company expected net sales to be in the range of $305 Million to $310 million.お知らせ • Jul 07AngioDynamics, Inc. to Report Q4, 2025 Results on Jul 15, 2025AngioDynamics, Inc. announced that they will report Q4, 2025 results Pre-Market on Jul 15, 2025お知らせ • Jun 24AngioDynamics Announces First Patient Enrolled in Recover-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary EmbolismAngioDynamics, Inc. announced the first patient has been enrolled in the RECOVER-AV clinical trial, a prospective, multi-center, multi-national, single-arm study evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute, intermediate-risk pulmonary embolism (PE). The study follows the United States Food and Drug Administration (FDA) 510(k) clearance of the AlphaVac F1885 System for the treatment of PE in the United States in April 2024 and its CE Mark approval in Europe in May 2024. The RECOVER-AV trial is designed to evaluate the safety and efficacy of the AlphaVac F 1885 System in support of its adoption in the Global market, as well as to assess long-term functional outcomes for patients following treatment. This study builds on the results of the Company's U.S.-based APEX-AV trial2, which demonstrated that the AlphaVac F18 85 System is safe and effective for use in intermediate-risk PE patients, with significant improvements in right ventricular function and reduction in clot burden. The AlphaVac F1885 system received CE Mark approval in May 2024 for the non-surgical removal of thrombi oremboli from the pulmonary arteries. The System is designed to support frontline treatment of PE and expand options for healthcare providers managing patients with life-threatening venous thromboembolism.お知らせ • Apr 02AngioDynamics, Inc. Revises Earnings Guidance for the Fiscal Year 2025AngioDynamics, Inc. revised earnings guidance for the fiscal year 2025. The company now revises net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.お知らせ • Mar 19AngioDynamics, Inc. to Report Q3, 2025 Results on Apr 02, 2025AngioDynamics, Inc. announced that they will report Q3, 2025 results Pre-Market on Apr 02, 2025お知らせ • Jan 30AngioDynamics, Inc. Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb IschemiaAngioDynamics, Inc. announced the start of a Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee (AMBITION BTK). AMBITION BTK is a multicenter, randomized controlled trial (RCT) designed to evaluate the clinical outcomes of the Auryon Atherectomy System in combination with standard balloon angioplasty compared to standard balloon angioplasty alone for the treatment of infrapopliteal lesions in patients with critical limb ischemia. The trial will enroll up to 200 subjects across up to 30 hospital-based sites. Additionally, up to 1,500 subjects treated with the Auryon Atherectomy System at the same sites who do not meet the eligibility criteria of the RCT will be enrolled in a companion Registry. Lower extremity peripheral artery disease (PAD) affects more than 230 million adults worldwide and is associated with an increased risk of various adverse clinical outcomes. In its most severe form, critical limb ischemia patients are often treated with lower extremity amputation (LEA). The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR) and to date, it has been used to treat more than 100,000 patients in the United States and worldwide. AMBITION BTK builds upon the positive outcomes of a prior multicenter, prospective trial that evaluated the safety and effectiveness of the Auryon laser atherectomy system in treating BTK lesions in patients with limb ischemia. The earlier study successfully treated 61 complex, calcified lesions across four U.S. centers in 60 patients, achieving strong clinical outcomes with minimal complications. These results demonstrated the System's ability to safely and effectively address challenging BTK cases, leading to the development of the AMBITION BTK RCT and Registry. The technology underlying the Auryon Atherectomy System has been shown in clinical studies to be effective in treating lesions ranging from soft plaque to severely calcified. The System uses a 355nm wavelength laser platform, enabling the use of short UV laser pulses with targeted biological reactions that are effective in treating PAD while minimizing the risk of perforation and preserving the ability to vaporize lesions without thermal ablation. On February 1, 2025, the Company will host its inaugural Cardiovascular Scientific Forum (CVSF). The event will bring together leading physicians and thought leaders in the cardiovascular field to present groundbreaking research, discuss emerging clinical trends, and showcase advancements shaping the future of patient care, including the AMBITION BTK RCT and Registry.お知らせ • Jan 14AngioDynamics, Inc. Announces Publication of Apex-Av Trial Results in JSCAIAngioDynamics, Inc. announced the publication of the results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI). The article, "Novel Mechanical Aspiration Thrombectomy in Patients with Acute Pulmonary Embolist: Results from the Prospective APEX-AV Trial," was published December 27, 2024. In December 2023, AngioDynamics announced the completion of patient enrollment in its APEX-AV trial, a single-arm Investigational Device Exemption study that enrolled 122 patients with confirmed acute, immediate-risk PE across 25 hospital-based sites in the United States to assess the AlphaVac F1885 System for the treatment of PE. In April 2024, the United States Food and Drug Administration (FDA) cleared the AlphaVac F18 85 System for the treatment of PE".お知らせ • Dec 20AngioDynamics, Inc. to Report Q2, 2025 Results on Jan 08, 2025AngioDynamics, Inc. announced that they will report Q2, 2025 results Pre-Market on Jan 08, 2025お知らせ • Dec 10AngioDynamics Receives FDA Clearance for the NanoKnife® System for Prostate Tissue AblationAngioDynamics, Inc. announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The Company received clearance for the NanoKnife System for prostate tissue ablation following the completion of the pivotal PRESERVE clinical study and submission of results to the FDA in September. The study evaluated the safety and effectiveness of the system for ablating prostate tissue in patients with intermediate-risk prostate cancer (PCa). Conducted in collaboration with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), PRESERVE enrolled 121 patients across 17 clinical sites. The PRESERVE clinical study met its primary effectiveness endpoint demonstrating the performance of the NanoKnife System for the ablation of prostate tissue in patients with intermediate-risk PCa. At 12-months post-procedure, 84.0% of men were free from in-field, clinically significant disease. In addition, the study demonstrated strong quality of life outcomes with short-term urinary continence being preserved (96.6% at baseline, 95.4% at 12-months) and the ability to maintain erections sufficient for intercourse only decreasing 9% compared to baseline (80.7% to 71.7%). The study’s results validated the robust safety and clinical efficacy profile of the NanoKnife System, reinforcing findings from more than 32 clinical studies performed around the world involving over 2,600 patients. Prostate cancer is the second most common cancer in men worldwide, with approximately 1.5 million new cases diagnosed annually. Many of these patients seek alternatives to radical procedures that can lead to significant, long-term urological side effects. The NanoKnife System is the first and only non-thermal, radiation-free, ablation technology designed to treat prostate tissue by using IRE technology, offering patients a minimally invasive option for prostate treatment. The NanoKnife System delivers an innovative alternative to conventional radical surgery or radiotherapy, which often results in significant dysfunction in urinary continence and erectile potency. With its non-thermal approach, the system is engineered to preserve vital structures inside and outside the prostate, offering patients improved outcomes, reduced recovery times, and enhanced quality of life.お知らせ • Oct 25AngioDynamics, Inc. Announces the Launch of an International Multi-Center Prospective Registry StudyAngioDynamics, Inc. announced the launch of an international multi-center prospective registry study to assess the long term effects of treating men with unifocal intermediate-risk prostate cancer with the NanoKnife System in partnership with the University College London Hospital (UCLH). Approximately 40% of all diagnosed prostate cancer cases are classified as intermediate risk. In the first year after surgery, 36% of men report urinary leakage, and 95% are affected by erectile dysfunction (70% described as moderate/severe). The NanoKnife System delivers an innovative alternative to conventional radical surgery or radiotherapy, each of which often results in significant dysfunction in urinary continence and erectile potency. With its non-thermal approach, the NanoKnife system is engineered to preserve vital structures inside and outside the prostate, offering patients effective treatment of tumors, low complication rates, and minimal impact on quality of life. AngioDynamics is conducting the international multi-center prospective registry study in partnership with UCLH. UCLH is the largest center for robotic prostate surgery in the U.K. and a leading provider of focal therapy, radiotherapy, robotic surgery, and active surveillance treatment options for men with prostate cancer. Additionally, UCLH was the first facility in the National Health Service to use the NanoKnife System to treat prostate cancer, and provide standardized patient selection, treatment, and long-term follow-up. The study will enroll a minimum of 500 patients worldwide to confirm the multiple single-center published papers indicating that the NanoKnife System is safe and effective in the treatment of targeted tumors, and the prevention or delayed need for radical intervention in the preservation of patient quality of life. Complementing the ongoing Randomized Controlled Trial studies evaluating NanoKnife versus radical treatment, this investigator-initiated trial will closely monitor patients post-treatment, measuring critical quality of life metrics and tracking any necessary follow-up interventions. In addition to quality of life, the study will assess overall and prostate-specific mortality rates.Recent Insider Transactions • Oct 10CEO, President & Director recently bought €110k worth of stockOn the 7th of October, James Clemmer bought around 20k shares on-market at roughly €5.49 per share. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €172k worth in shares.Breakeven Date Change • Oct 06No longer forecast to breakevenThe 3 analysts covering AngioDynamics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.20m in 2027. New consensus forecast suggests the company will make a loss of US$2.00m in 2027.Reported Earnings • Oct 04First quarter 2025 earnings released: US$0.32 loss per share (vs US$1.15 profit in 1Q 2024)First quarter 2025 results: US$0.32 loss per share (down from US$1.15 profit in 1Q 2024). Revenue: US$67.5m (down 14% from 1Q 2024). Net loss: US$12.8m (down 128% from profit in 1Q 2024). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.お知らせ • Oct 03AngioDynamics, Inc. Provides Earnings Guidance for the Year 2025AngioDynamics, Inc. provided earnings guidance for the year 2025. For fiscal year 2025, the Company continues to expects net sales to be in the range of $282 to $288 million, representing growth of between 4.2% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.New Risk • Sep 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).お知らせ • Sep 27AngioDynamics, Inc., Annual General Meeting, Nov 12, 2024AngioDynamics, Inc., Annual General Meeting, Nov 12, 2024.お知らせ • Sep 19AngioDynamics, Inc. to Report Q1, 2025 Results on Oct 03, 2024AngioDynamics, Inc. announced that they will report Q1, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 03, 2024Reported Earnings • Jul 17Full year 2024 earnings released: US$4.59 loss per share (vs US$1.33 loss in FY 2023)Full year 2024 results: US$4.59 loss per share (further deteriorated from US$1.33 loss in FY 2023). Revenue: US$303.9m (down 10% from FY 2023). Net loss: US$184.3m (loss widened 252% from FY 2023). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.Breakeven Date Change • Jul 17Forecast to breakeven in 2027The 3 analysts covering AngioDynamics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$1.20m in 2027. Average annual earnings growth of 97% is required to achieve expected profit on schedule.お知らせ • Jul 16+ 1 more updateAngioDynamics, Inc. (NasdaqGS:ANGO) announces an Equity Buyback for $15 million worth of its shares.AngioDynamics, Inc. (NasdaqGS:ANGO) announces a share repurchase program. Under the program, the company will repurchase up to $15 million worth of its shares.お知らせ • Jul 09AngioDynamics, Inc. to Report Q4, 2024 Results on Jul 16, 2024AngioDynamics, Inc. announced that they will report Q4, 2024 results Pre-Market on Jul 16, 2024New Risk • Jun 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.1m net loss in 3 years). Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).New Risk • Apr 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.1m net loss in 3 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).Recent Insider Transactions • Apr 09CEO, President & Director recently bought €62k worth of stockOn the 8th of April, James Clemmer bought around 10k shares on-market at roughly €6.17 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.Reported Earnings • Apr 05Third quarter 2024 earnings released: US$4.73 loss per share (vs US$0.24 loss in 3Q 2023)Third quarter 2024 results: US$4.73 loss per share (further deteriorated from US$0.24 loss in 3Q 2023). Revenue: US$75.2m (down 6.9% from 3Q 2023). Net loss: US$190.4m (loss widened US$181.0m from 3Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Board Change • Apr 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Karen Licitra was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 05AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024AngioDynamics, Inc. provided sales guidance for the Fiscal Year 2024. For the year, the company expects net sales to be in the range of $270 million to $275 million which reflects the recent divestiture of the PICC and Midline businesses and discontinuance of the RadioFrequency ablation and Syntrax businesses, which accounted for approximately $50 million of the prior revenue guidance of $320 to $325 million. The Company expects gross margin to be approximately 52.0% to 54.0%.お知らせ • Apr 04+ 1 more updateAngioDynamics, Inc. Reports Consolidated Goodwill Impairment for Third Quarter Ended February 29, 2024AngioDynamics, Inc. reported consolidated Goodwill impairment for third quarter ended February 29, 2024. For the quarter, the company reported Goodwill impairment of $159,476,000.お知らせ • Apr 02Angiodynamics Announces Settlement of All Patent Litigation with C.R. Bard, IncAngioDynamics, Inc. announced that it has entered into a settlement agreement with Becton, Dickinson and Company (BD) to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD. Under the terms of the settlement, BD will grant a license to AngioDynamics under certain of BD’s port patents and AngioDynamics will grant BD a license under certain of AngioDynamics’ catheter patents. AngioDynamics will make a one-time lump sum payment to BD in the amount of $7 million, $3 million of which will be paid within five days and the balance of which will be payable of installments over the next 12 months. AngioDynamics will also make six minimum annual payments to BD of $2.5 million through February 2029, and potential additional payments if six percent (6%) of annual net sales of AngioDynamics’ port products exceed the minimum payment. The parties will participate in the pending appeal before the Federal Circuit of the case titled C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. v. AngioDynamics, Inc. (C.A. 15-00218–JFB; and CAFC appeal No. 23-2056) and a contingent payment of $3 million will be due from AngioDynamics to BD if the Federal Circuit reverses or vacates the District Court’s findings of invalidity with respect to the patent claims at issue the case. The agreement contains mutual covenants not to sue and releases. Neither party admitted any liability in connection with the settlement agreement. The agreement concludes a multi-year patent dispute between the parties.お知らせ • Mar 20AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024AngioDynamics, Inc. announced that they will report Q3, 2024 results Pre-Market on Apr 04, 2024お知らせ • Feb 16Angiodynamics, Inc. Announces Board ChangesAngioDynamics, Inc. announced that on February 8, 2024 the Board appointed Wesley Johnson as the new chair of the Audit Committee and Jan Stern Reed as the new chair of the Nominating, Compliance and Corporate Governance Committee. James Clemmer resigned from his position as a Class II director on the Board and was immediately re-appointed as a Class I director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders. The resignation and reappointment of Mr. Clemmer was effected solely for the purpose of rebalancing each class of directors to consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board, and for all other purposes, Mr. Clemmer’s service on the Board is deemed to have continued uninterrupted.お知らせ • Jan 23+ 1 more updateAngiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial DiseaseAngioDynamics, Inc. announced that the United States Food and Drug Administration (FDA) has cleared the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in the treatment of Peripheral Arterial Disease (PAD). According to the American Heart Association, PAD affects 8.5 million Americans and 200 million people worldwide each year. Studies have shown that radial access is associated with a significantly lower risk of major bleeding and access site complications when compared to femoral access in the treatment of patients. The Auryon XL Catheter, available in 0.9 mm and 1.5 mm diameters, expands treatment access points in atherectomy procedures for PAD. Use of a general radial access catheter may reduce incidents of major bleeding, when compared to femoral access, by more than 70%. Additionally, it may eliminate the need for the use of femoral closure devices and allow for the treatment of bilateral disease in a single session, supporting improved patient mobility, earlier discharge and faster patient recovery times. Following FDA 510(k) clearance, AngioDynamics initiated a limited market release of the Auryon XL Catheter in the United States in January 2024 and expects to enter full market release in February 2024. The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR), and to date, it has been used to treat more than 50,000 patients7 in the United States. The technology underlying the Auryon Atherectomy System has been shown in clinical studies to be effective in treating lesions ranging from soft plaque to severely calcified5,6,8. The System uses a 355nm wavelength laser platform, enabling the use of short UV laser pulses with targeted biological reactions that are effective in treating PAD while minimizing the risk of perforation and preserving the ability to vaporize lesions without thermal ablation.お知らせ • Jan 05+ 2 more updatesAngioDynamics, Inc. Announces Manufacturing Operations RestructuringAngioDynamics, Inc. announced that it is committed to shifting its manufacturing operations from a company-owned facility in upstate New York to a fully outsourced model over the next two years. This shift is expected to result in an approximate $15 million annualized reduction in expenses by fiscal year 2027.お知らせ • Dec 08AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024AngioDynamics, Inc. announced that they will report Q2, 2024 results Pre-Market on Jan 05, 2024お知らせ • Dec 07AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary EmbolismAngioDynamics, Inc. announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company's AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute intermediate-risk pulmonary embolism (PE). PERT represents the third-leading cause of cardiovascular mortality in the United States. APEX-AV is a single-arm Investigational Device Exemption study that enrolled 122 patients with confirmed acute, intermediate-risk PE across 25 hospital-based sites in the United States. The primary efficacy endpoint of the APEX-AV Study is the reduction in RV/LV ratio between baseline and 48 hours post-procedure. The primary safety endpoint is the rate of Major Adverse Events (MAEs), including device-related death and major bleeding within the first 48 hours. Patients will be followed for 30 days post-index procedure. AngioDynamics initiated the APEX-AV Study in partnership with the widely respected Pulmonary Embolism Response Team (PERT) Consortium™. The study is led by co-Principal Investigators William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™ and Mona Ranade, MD, Assistant Professor, Interventional Radiology, at the David Geffen School of Medicine at UCLA. Pulmonary embolism (PE) can be a life-threatening condition that affects around 900,000 people in the United States every year.2 In most cases, PE is caused by blood clots in the legs, called deep vein thrombosis, that travel to the lungs.2 Patients with submassive or intermediate-risk PE account for 35% to 55% of hospitalized patients with PE and have a mortality rate of 3 to 14%.New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Large one-off items impacting financial results.お知らせ • Oct 06Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024AngioDynamics, Inc. provided earning guidance for fiscal year 2024. The Company continues to expect its fiscal year 2024 net sales to be in the range of $328to $333 million and gross margin to be approximately 50% to 52%. For comparison, pro forma revenue, gross margin, and adjusted loss per share for FY23 when excluding the assets divested to Merit Medical were $306.3 million, 50.5%, and $0.43, respectively.Reported Earnings • Oct 05First quarter 2024 earnings released: EPS: US$1.15 (vs US$0.33 loss in 1Q 2023)First quarter 2024 results: EPS: US$1.15 (up from US$0.33 loss in 1Q 2023). Revenue: US$78.7m (down 3.5% from 1Q 2023). Net income: US$45.9m (up US$58.9m from 1Q 2023). Profit margin: 58% (up from net loss in 1Q 2023). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Sep 29AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023, at 12:00 US Eastern Standard Time. Agenda: To consider and vote upon a proposal to elect four Class II directors, for a term of three years; to consider and vote upon a proposal to ratify the appointment of AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2024; to consider and vote upon a "Say-on-Pay" advisory vote on the approval of the compensation of AngioDynamics' named executive officers; to consider and vote upon a proposal to amend the AngioDynamics, Inc. 2020 Equity Incentive Plan to, among other things, increase the number of shares available for issuance; to hold a "Say-On-Pay Frequency" advisory vote on a non-binding resolution to determine the frequency our shareholders will be asked to approve the compensation of our named executive officers; and transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.お知らせ • Sep 13AngioDynamics, Inc. to Report Q1, 2024 Results on Oct 04, 2023AngioDynamics, Inc. announced that they will report Q1, 2024 results Pre-Market on Oct 04, 2023お知らせ • Aug 17AngioDynamics, Inc. Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart VegetationAngioDynamics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company's AngioVac System for the proposed indications for use to include the non-surgical removal of vegetation from the right heart. The FDA Breakthrough Device designation is designed to help patients gain timely access to medical devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions for which no approved or cleared alternatives exist. Target vessels for the thrombus/embolus extraction include, but are not limited to, the iliofemoral vein, Inferior Vena Cava (IVC), Superior Vena Cava (SVC) and Right Heart. Under the Breakthrough Device designation, AngioDynamics will engage with the FDA to achieve this new expanded indication for the non-surgical removal from the right heart. The accelerated pathway expedites assessment and review processes of the AngioVac System and allows for more interactive and timely communication with the FDA, efficient and flexible clinical study design, FDA review team support, Agency senior management engagement and priority review.お知らせ • Aug 04Angiodynamics, Inc. Completes Enrollment for Preserve Clinical StudyAngioDynamics, Inc. announced the completion of enrollment and final treatment in its Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population (PRESERVE). The PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC). Final patient enrollment in the study was initially announced during AngioDynamics’ Fiscal 2023 Fourth Quarter and Full-Year Financial Results conference call on July 12, 2023. Co-Principal Investigators leading the study are Jonathan Coleman, MD, Urologic Surgeon, Memorial Sloan Kettering Cancer Center, and Arvin George, MD, Urologic Surgeon, University of Michigan. The PRESERVE study will have its primary endpoint analysis at 12 months following treatment. In 2023, the American Cancer Society estimates that there will be about 288,300 new cases of prostate cancer and about 34,700 deaths from the disease in the U.S. It is estimated that 1 out of every 8 men will be diagnosed with prostate cancer during their lifetime, and prostate cancer is more likely to develop in older and non-Hispanic Black men. It is American men's second leading cause of death. The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted tissue, delivering precise treatment margins while preserving vital structures by retaining the structural integrity of the targeted tissue. The delivery of non-thermal energy allows for the preservation of the extra-cellular matrix, facilitating post-ablation histological and functional tissue regeneration. The PRESERVE study’s primary objectives are determining the NanoKnife System’s ablation effectiveness by measuring the negative in-field biopsy rate at 12 months and determining the NanoKnife System’s procedural and post-procedural safety profile by evaluating adverse event incidence, type and severity through 12 months. The study enrolled and treated 121 patients in 17 facilities across the United States.お知らせ • Jul 25AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of DirectorsAngioDynamics, Inc. announced the appointment of Lorinda Burgess to the Company’s Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company’s Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. Ms. Burgess was most recently Chief Financial Officer and Vice President of Finance for the Americas Region at Medtronic, Inc., a Fortune 200 global medical device company with more than $30 billion in annual revenues. Prior to this role, Ms. Burgess also served as Vice President of Customer Care for the Americas and Western Europe at Medtronic, Inc. and Vice President of Finance for the Cardiovascular Group’s Sales and Marketing function. Ms. Burgess earned a Bachelor of Arts in Communication and Political Science from the University of Michigan and a Master’s in Business Administration from Ohio State University. Ms. Burgess is a member of the Board of Directors for Stepan Company. With Ms. Burgess’ appointment, AngioDynamics’ total number of directors will increase to nine members.お知らせ • Jul 13AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024AngioDynamics, Inc. provided financial guidance for the fiscal year 2024. The company anticipates that fiscal year 2024 revenue will be in the range of $328 million to $333 million.Reported Earnings • Jul 13Full year 2023 earnings released: US$1.33 loss per share (vs US$0.68 loss in FY 2022)Full year 2023 results: US$1.33 loss per share (further deteriorated from US$0.68 loss in FY 2022). Revenue: US$338.8m (up 7.1% from FY 2022). Net loss: US$52.4m (loss widened 98% from FY 2022). Revenue is forecast to grow 2.3% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Jun 21AngioDynamics, Inc. to Report Q4, 2023 Results on Jul 12, 2023AngioDynamics, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Jul 12, 2023New Risk • Jun 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$37m Forecast net loss in 2 years: US$14m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$14m net loss in 2 years). Share price has been volatile over the past 3 months (7.2% average weekly change).お知らせ • Jun 09Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million.Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million on June 8, 2023. The transaction was financed at closing through borrowings available under its long-term credit facility. The acquired assets generated approximately $33 million of revenue over the trailing twelve months ended May 31, 2023. The transaction will be dilutive to adjusted earnings per share and is expected to be slightly dilutive to corporate gross margins of AngioDynamics, Inc. Piper Sandler & Co. acted as lead financial advisor to Merit and Oppenheimer & Co. acted as a financial advisor to Merit. UBS Investment Bank acted as financial advisor to AngioDynamics, Inc. Parr Brown Gee & Loveless P.C. served as legal advisor to Merit. Cadwalader Wickersham & Taft served as legal advisor to AngioDynamics. Oppenheimer & Co. Inc. acted as financial advisor to Merit Medical Systems, Inc. Merit Medical Systems, Inc. (NasdaqGS:MMSI) completed the acquisition of Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) on June 8, 2023.Breakeven Date Change • May 31Forecast to breakeven in 2026The 4 analysts covering AngioDynamics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$11.7m in 2026. Average annual earnings growth of 66% is required to achieve expected profit on schedule.Reported Earnings • Mar 31Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.13 loss in 3Q 2022)Third quarter 2023 results: US$0.24 loss per share (further deteriorated from US$0.13 loss in 3Q 2022). Revenue: US$80.7m (up 9.1% from 3Q 2022). Net loss: US$9.49m (loss widened 91% from 3Q 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Feb 03Key Executive recently sold €55k worth of stockOn the 31st of January, David Helsel sold around 5k shares on-market at roughly €11.92 per share. This transaction amounted to 37% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. David has been a net seller over the last 12 months, reducing personal holdings by €240k.お知らせ • Jan 06AngioDynamics, Inc. Reaffirms Revenue Guidance for Fiscal 2023AngioDynamics, Inc. reaffirms revenue Guidance for fiscal 2023. Management expects net sales to be in the range of $342 to $348 million.Reported Earnings • Jan 06Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.21 loss in 2Q 2022)Second quarter 2023 results: US$0.21 loss per share (further deteriorated from US$0.21 loss in 2Q 2022). Revenue: US$85.4m (up 9.1% from 2Q 2022). Net loss: US$8.49m (loss widened 1.6% from 2Q 2022). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Breakeven Date Change • Jan 06The 4 analysts covering AngioDynamics previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 5.7% per year to 2024. The company is expected to make a profit of US$1.00m in 2025.お知らせ • Dec 16AngioDynamics, Inc. to Report Q2, 2023 Results on Jan 05, 2023AngioDynamics, Inc. announced that they will report Q2, 2023 results at 9:30 AM, US Eastern Standard Time on Jan 05, 2023Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Jan Reed was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Nov 01AngioDynamics, Inc. Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary EmbolismAngioDynamics, Inc. announced the enrollment of the first patient in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV), a clinical study aimed at evaluating the efficacy and safety of the Company’s AlphaVac Multipurpose Mechanical Aspiration (MMA) F18 System in the treatment of acute intermediate-risk pulmonary embolism (PE). APEX-AV is a single-arm Investigational Device Exemption study enrolling patients with confirmed acute, intermediate-risk PE at up to 20 hospital-based sites in the United States. The primary efficacy endpoint of the APEX-AV Study is the reduction in RV/LV ratio between baseline and 48 hours post-procedure. The primary safety endpoint is the rate of Major Adverse Events (MAEs), including device-related death and major bleeding within the first 48 hours. Patients will be followed for 30 days post-index procedure. Pulmonary embolism can be a life-threatening condition and affects approximately 1 in 1,000 people in the U.S. every year. AngioDynamics initiated the APEX-AV Study in partnership with the widely respected Pulmonary Embolism Response Team (PERT) Consortium™. The Study is led by co-Principal Investigators William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and President, The PERT Consortium™ and Mona Ranade, MD, Assistant Professor, Interventional Radiology, at the David Geffen School of Medicine at UCLA.Recent Insider Transactions • Oct 12CEO, President & Director recently bought €155k worth of stockOn the 10th of October, James Clemmer bought around 10k shares on-market at roughly €15.47 per share. This transaction amounted to 2.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €356k worth in shares.Reported Earnings • Oct 07First quarter 2023 earnings released: US$0.33 loss per share (vs US$0.18 loss in 1Q 2022)First quarter 2023 results: US$0.33 loss per share (further deteriorated from US$0.18 loss in 1Q 2022). Revenue: US$81.5m (up 5.9% from 1Q 2022). Net loss: US$13.0m (loss widened 87% from 1Q 2022). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 18% per year.お知らせ • Oct 07AngioDynamics, Inc. Reaffirms Earnings Guidance for the Year 2023AngioDynamics, Inc. reaffirms earnings guidance for the year 2023. Management is reaffirming its previously issued fiscal year 2023 guidance. Management expects net sales to be in the range of $342 to $348 million.お知らせ • Sep 23AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022, at 12:00 US Eastern Standard Time. Agenda: To consider and vote upon a proposal to elect two class i directors, for a term of three years; to ratify the appointment of angiodynamics’ independent registered public accounting firm for the fiscal year ending may 31, 2023; to consider and vote upon a “say-on-pay” advisory vote on the approval of the compensation of angiodynamics’ named executive officers; to vote upon a proposal to approve an in increase the number of shares available for issuance under the angiodynamics, inc. 2020 equity incentive plan; to vote upon a proposal to approve an increase in the number of shares available for issuance under the angiodynamics, inc. employee stock purchase plan; and to transact such other business as may properly come before the meeting or any adjournment or postponement thereof.お知らせ • Sep 09AngioDynamics, Inc. to Report Q1, 2023 Results on Oct 06, 2022AngioDynamics, Inc. announced that they will report Q1, 2023 results Pre-Market on Oct 06, 2022Recent Insider Transactions • Aug 03Key Executive recently sold €110k worth of stockOn the 29th of July, David Helsel sold around 5k shares on-market at roughly €22.00 per share. This was the largest sale by an insider in the last 3 months. David has been a seller over the last 12 months, reducing personal holdings by €269k.Reported Earnings • Jul 13Full year 2022 earnings released: US$0.68 loss per share (vs US$0.82 loss in FY 2021)Full year 2022 results: US$0.68 loss per share (up from US$0.82 loss in FY 2021). Revenue: US$316.2m (up 8.7% from FY 2021). Net loss: US$26.5m (loss narrowed 16% from FY 2021). Over the next year, revenue is forecast to grow 8.2%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Breakeven Date Change • Jul 13Forecast to breakeven in 2025The 4 analysts covering AngioDynamics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 29% per year to 2024. The company is expected to make a profit of US$1.40m in 2025. Average annual earnings growth of 63% is required to achieve expected profit on schedule.お知らせ • Jul 13AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2023AngioDynamics, Inc. provided sales guidance for the fiscal year 2023. for the year, the company expects net sales to be in the range of $342 million to $348 million.お知らせ • Jun 16AngioDynamics, Inc. to Report Q4, 2022 Results on Jul 12, 2022AngioDynamics, Inc. announced that they will report Q4, 2022 results Pre-Market on Jul 12, 2022Recent Insider Transactions • May 03Key Executive recently sold €75k worth of stockOn the 28th of April, David Helsel sold around 4k shares on-market at roughly €21.32 per share. In the last 3 months, there was an even bigger sale from another insider worth €159k. David has been a seller over the last 12 months, reducing personal holdings by €159k.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Jan Reed was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Apr 08Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.092 loss in 3Q 2021)Third quarter 2022 results: US$0.13 loss per share (down from US$0.092 loss in 3Q 2021). Revenue: US$74.0m (up 3.9% from 3Q 2021). Net loss: US$4.96m (loss widened 40% from 3Q 2021). Over the next year, revenue is forecast to grow 8.4%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.お知らせ • Apr 08AngioDynamics, Inc. Provides Earnings Guidance for the Year 2022AngioDynamics, Inc. provided earnings guidance for the year 2022. For the year, the company net sales to be in the range of $310 to $315 million.Recent Insider Transactions • Jan 19CEO, President & Director recently bought €201k worth of stockOn the 11th of January, James Clemmer bought around 10k shares on-market at roughly €20.10 per share. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.お知らせ • Jan 07AngioDynamics, Inc. Reports Impairment for the Three Months Ended November 30, 2021AngioDynamics, Inc. reported impairment for the three months ended November 30, 2021. Fixed and intangible asset impairments and disposals was $67,000 against $90,000 a year ago.Reported Earnings • Jan 07Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: US$0.21 loss per share (down from US$0.11 loss in 2Q 2021). Revenue: US$78.3m (up 7.6% from 2Q 2021). Net loss: US$8.35m (loss widened 96% from 2Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 7.2%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Jan 07AngioDynamics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022AngioDynamics, Inc. reiterated earnings guidance for the fiscal year 2022. The Company continues to expect its fiscal year 2022 net sales to be in the range of $310 to $315 million.Recent Insider Transactions • Oct 23Key Executive recently sold €84k worth of stockOn the 20th of October, David Helsel sold around 3k shares on-market at roughly €24.02 per share. This was the largest sale by an insider in the last 3 months. David has been a seller over the last 12 months, reducing personal holdings by €154k.Reported Earnings • Oct 03First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$77.0m (up 9.6% from 1Q 2021). Net loss: US$6.97m (loss widened 63% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Reported Earnings • Jul 16Full year 2021 earnings released: US$0.82 loss per share (vs US$4.39 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: US$291.0m (up 10% from FY 2020). Net loss: US$31.5m (loss narrowed 81% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.株主還元UG2DE Medical EquipmentDE 市場7D-1.6%1.6%-0.5%1Y61.0%-25.4%0.3%株主還元を見る業界別リターン: UG2過去 1 年間で-25.4 % の収益を上げたGerman Medical Equipment業界を上回りました。リターン対市場: UG2過去 1 年間で0.3 % の収益を上げたGerman市場を上回りました。価格変動Is UG2's price volatile compared to industry and market?UG2 volatilityUG2 Average Weekly Movement6.0%Medical Equipment Industry Average Movement6.3%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: UG2 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: UG2の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1988632Jim Clemmerwww.angiodynamics.comAngioDynamics, Inc.は、医療技術企業であり、米国内外で末梢血管疾患、腫瘍学、外科的治療に使用される医療機器、外科機器、診断機器の設計、製造、販売に従事している。同社は、血管壁内皮を温存しながら病変を除去するために最適化された波長、パルス幅、振幅を提供するように設計されたAuryon Atherectomyシステムを提供している。同社の血栓管理ポートフォリオには、灌流技師のサポートを不要にする緊急機械的吸引装置であるAlphaVac機械的血栓除去システム、血液透析アクセスグラフト、動脈、静脈、外科的バイパスグラフト内の血栓を溶解する薬剤である血栓溶解剤を送達するために使用される血栓溶解カテーテルが含まれる；アンジオバック静脈ドレナージカニューレと体外循環回路は、体外循環バイパス術の一部として静脈ドレナージを促進するために、既製のポンプ、フィルター、再灌流カニューレを含み、最長6時間の体外循環補助に適応される。また、従来の熱アブレーションに代わる軟部組織の外科的アブレーションシステムであるナノナイフIREアブレーションシステムや、血管造影カテーテル、診断・介入用ガイドワイヤー、経皮的ドレナージカテーテル、末梢診断・介入手技で使用する同軸マイクロイントロデューサーキットなどの末梢製品も提供している。さらに、多目的/一般、腎瘻、胆道ドレナージ用のドレナージカテーテル、マイクロアクセスキットは、インターベンション医に低侵襲処置用の小型のイントロデューサーシステムを提供する、ベナキュアEVLTシステムは、表在静脈疾患を治療する血管内レーザー処置で使用される、ソレロMTAシステムは、ソレロマイクロ波発生器と特別に設計されたソレロMWアプリケータを含む。同社は1988年に設立され、ニューヨーク州レーサムに本社を置いている。もっと見るAngioDynamics, Inc. 基礎のまとめAngioDynamics の収益と売上を時価総額と比較するとどうか。UG2 基礎統計学時価総額€515.22m収益（TTM）-€32.21m売上高(TTM)€280.66m1.8xP/Sレシオ-16.0xPER（株価収益率UG2 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計UG2 損益計算書（TTM）収益US$320.17m売上原価US$145.28m売上総利益US$174.89mその他の費用US$211.63m収益-US$36.74m直近の収益報告May 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.89グロス・マージン54.62%純利益率-11.48%有利子負債／自己資本比率3.4%UG2 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 18:49終値2026/07/21 00:00収益2026/05/31年間収益2026/05/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AngioDynamics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Matthew TaylorBarclaysJohn YoungCanaccord GenuityWilliam PlovanicCanaccord Genuity13 その他のアナリストを表示
Reported Earnings • Jul 15Full year 2026 earnings released: US$0.89 loss per share (vs US$0.83 loss in FY 2025)Full year 2026 results: US$0.89 loss per share (further deteriorated from US$0.83 loss in FY 2025). Revenue: US$320.2m (up 9.5% from FY 2025). Net loss: US$36.7m (loss widened 8.1% from FY 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 14AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2027AngioDynamics, Inc. provided earnings guidance for the Fiscal Year 2027. For the year, the Company expected net sales to be in the range of $336 million to $341 million.
お知らせ • Jun 30AngioDynamics, Inc. to Report Q4, 2026 Results on Jul 14, 2026AngioDynamics, Inc. announced that they will report Q4, 2026 results at 9:30 AM, US Eastern Standard Time on Jul 14, 2026
お知らせ • Jun 17AngioDynamics Receives FDA IDE Approval For RELIEF Feasibility Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment For Benign Prostatic HyperplasiaAngioDynamics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). BPH is among the most prevalent urologic conditions affecting men in the United States, with an estimated 15 million men exhibiting symptoms and more than 300,000 surgical procedures performed annually. BPH can cause lower urinary tract symptoms, including urinary frequency, urgency, weak stream, and incomplete bladder emptying, that impair daily function and quality of life. Current treatment options range from pharmacologic therapy to surgical interventions such as transurethral resection of the prostate (TURP) and newer minimally invasive procedures, underscoring the need for additional approaches that balance effectiveness with preservation of sexual and urinary function. The NanoKnife System is cleared for the surgical ablation of prostate tissue. In prior clinical experience with IRE in the prostate, physicians observed meaningful improvements in urinary symptoms associated with BPH in patients treated for intermediate-risk prostate disease, an observation that provided clinical rationale for the RELIEF study. The RELIEF study is a prospective, single-arm clinical study that will enroll 40 subjects at up to five clinical sites in the United States. Patients, at six months post-treatment, will be evaluated for the primary endpoints and will also be followed for a total of five years for secondary endpoints. The primary effectiveness endpoint is the mean change in International Prostate Symptom Score (IPSS) from baseline to six months post-procedure. The primary safety endpoint is the incidence and severity of device-related adverse events during that period. RELIEF will evaluate the preliminary safety and effectiveness of IRE delivered via the NanoKnife System for the relief of BPH-related symptoms. The results will establish the evidence foundation for future clinical development of IRE as a minimally invasive treatment option for BPH. The study incorporates validated, well-established endpoints such as IPSS, uroflowmetry, and quality-of-life measures, alongside careful monitoring of sexual function and long-term durability through five years of follow-up. In the RELIEF study, electrodes are placed transperineally into predefined treatment zones of the prostate under transrectal ultrasound guidance and general anesthesia. Treatment planning targets the transition zone bilaterally while preserving critical structures, including the neurovascular bundles, external sphincter, and urethra. The NanoKnife System delivers short pulses of electrical energy to create permanent nanopores in cell membranes, resulting in precise, non-thermal ablation of prostate tissue. The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. United States: The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. Canada: The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability. European Union: The NanoKnife System is indicated for the ablation of soft tissue and tumors of the pancreas, kidney, liver, or prostate, including intermediate risk prostate cancer. The NanoKnife System has not received clearance for the therapy or treatment of any specific disease or condition. The NanoKnife System when used for the treatment of benign prostate hyperplasia is an investigational device. Limited by United States law to investigational use.
Breakeven Date Change • May 20No longer forecast to breakevenThe 4 analysts covering AngioDynamics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$700.0k in 2028. New consensus forecast suggests the company will make a loss of US$12.1m in 2028.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Karen Licitra was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Jul 15Full year 2026 earnings released: US$0.89 loss per share (vs US$0.83 loss in FY 2025)Full year 2026 results: US$0.89 loss per share (further deteriorated from US$0.83 loss in FY 2025). Revenue: US$320.2m (up 9.5% from FY 2025). Net loss: US$36.7m (loss widened 8.1% from FY 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 14AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2027AngioDynamics, Inc. provided earnings guidance for the Fiscal Year 2027. For the year, the Company expected net sales to be in the range of $336 million to $341 million.
お知らせ • Jun 30AngioDynamics, Inc. to Report Q4, 2026 Results on Jul 14, 2026AngioDynamics, Inc. announced that they will report Q4, 2026 results at 9:30 AM, US Eastern Standard Time on Jul 14, 2026
お知らせ • Jun 17AngioDynamics Receives FDA IDE Approval For RELIEF Feasibility Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment For Benign Prostatic HyperplasiaAngioDynamics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). BPH is among the most prevalent urologic conditions affecting men in the United States, with an estimated 15 million men exhibiting symptoms and more than 300,000 surgical procedures performed annually. BPH can cause lower urinary tract symptoms, including urinary frequency, urgency, weak stream, and incomplete bladder emptying, that impair daily function and quality of life. Current treatment options range from pharmacologic therapy to surgical interventions such as transurethral resection of the prostate (TURP) and newer minimally invasive procedures, underscoring the need for additional approaches that balance effectiveness with preservation of sexual and urinary function. The NanoKnife System is cleared for the surgical ablation of prostate tissue. In prior clinical experience with IRE in the prostate, physicians observed meaningful improvements in urinary symptoms associated with BPH in patients treated for intermediate-risk prostate disease, an observation that provided clinical rationale for the RELIEF study. The RELIEF study is a prospective, single-arm clinical study that will enroll 40 subjects at up to five clinical sites in the United States. Patients, at six months post-treatment, will be evaluated for the primary endpoints and will also be followed for a total of five years for secondary endpoints. The primary effectiveness endpoint is the mean change in International Prostate Symptom Score (IPSS) from baseline to six months post-procedure. The primary safety endpoint is the incidence and severity of device-related adverse events during that period. RELIEF will evaluate the preliminary safety and effectiveness of IRE delivered via the NanoKnife System for the relief of BPH-related symptoms. The results will establish the evidence foundation for future clinical development of IRE as a minimally invasive treatment option for BPH. The study incorporates validated, well-established endpoints such as IPSS, uroflowmetry, and quality-of-life measures, alongside careful monitoring of sexual function and long-term durability through five years of follow-up. In the RELIEF study, electrodes are placed transperineally into predefined treatment zones of the prostate under transrectal ultrasound guidance and general anesthesia. Treatment planning targets the transition zone bilaterally while preserving critical structures, including the neurovascular bundles, external sphincter, and urethra. The NanoKnife System delivers short pulses of electrical energy to create permanent nanopores in cell membranes, resulting in precise, non-thermal ablation of prostate tissue. The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. United States: The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. Canada: The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability. European Union: The NanoKnife System is indicated for the ablation of soft tissue and tumors of the pancreas, kidney, liver, or prostate, including intermediate risk prostate cancer. The NanoKnife System has not received clearance for the therapy or treatment of any specific disease or condition. The NanoKnife System when used for the treatment of benign prostate hyperplasia is an investigational device. Limited by United States law to investigational use.
Breakeven Date Change • May 20No longer forecast to breakevenThe 4 analysts covering AngioDynamics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$700.0k in 2028. New consensus forecast suggests the company will make a loss of US$12.1m in 2028.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Independent Director Karen Licitra was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 14AngioDynamics Announces Two-Year Preserve Trial Data Demonstrating Durable Nanoknife Ire System Outcomes In Intermediate-Risk Prostate CancerAngioDynamics, Inc. announced two-year results from the PRESERVE pivotal trial (NCT04972097) demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of intermediate-risk prostate cancer. The PRESERVE trial is a prospective, single-arm pivotal IDE study evaluating focal irreversible electroporation (IRE) using the NanoKnife System in 121 patients with Gleason Grade Group 2–3 intermediate-risk prostate cancer, conducted across 17 U.S. clinical centers in collaboration with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC). Primary 12-month results, published in European Urology in July 2025, demonstrated an 80% freedom-from-treatment-failure rate among protocol-biopsied patients. At 24 months, the updated findings confirm durability of outcomes: 94.4% of analysis-eligible patients (68 of 72) completed the 24-month assessment, reflecting strong cohort retention. No new treatment failures were identified among patients with available follow-up at 24 months. One patient (1.5%) underwent a clinically indicated biopsy, which was negative for any cancer. 97% of patients (66 of 68) had a PSA at 24 months below their baseline value. No new device- or procedure-related adverse events were reported between the 12- and 24-month assessments. The 24-month PRESERVE data complement an international long-term evidence base for focal IRE, including median five-year outcomes from a 2023 international multi-institutional cohort demonstrating sustained oncologic control and preservation of functional outcomes. PRESERVE Trial — 24-Month Results Summary: Focal IRE Ablation Using the NanoKnife System for Intermediate-Risk Prostate Cancer. Study Design: Parameter Detail. Trial Name PRESERVE (NCT04972097). Study Type Prospective, single-arm, pivotal IDE study. Technology NanoKnife System — Focal Irreversible Electroporation (IRE). Population Gleason Grade Group 2–3 (Gleason 3+4 or 4+3), clinical stage =T2c intermediate-risk prostate cancer. Sites 17 U.S. clinical centers. Partner Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC). Sponsor AngioDynamics, Inc. Key 24-Month Results: Endpoint Result. Total Enrolled 121 patients. 24-Month Analysis-Eligible 72 patients. 24-Month Completers 68 of 72 (94.4%). New Treatment Failures (12–24 mo) 0. Clinically Triggered Biopsies 1 (negative for any cancer). PSA Below Baseline at 24 Months 66 of 68 (97%). New Device/Procedure-Related AEs (12–24 mo) 0. 12-Month Primary Endpoint (Reference): Endpoint Result. Freedom from Treatment Failure 80% among protocol-biopsied patients. Publication European Urology, July 2025 (George et al.). With a growing body of prospective U.S. pivotal data and long-term international evidence supporting the safety and efficacy of focal IRE, the NanoKnife System continues to gain traction as a meaningful treatment option for men with intermediate-risk prostate cancer who seek durable oncologic control while preserving quality of life. AngioDynamics is advancing the NanoKnife IRE System evidence base and the reimbursement infrastructure needed to bring this option to more patients and physicians across care settings. The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. United States: The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. Canada: The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability. European Union: The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer.
お知らせ • Apr 02Angiodynamics, Inc. Provides Earnings Guidance for Fiscal Year 2026AngioDynamics, Inc. provided earnings guidance for fiscal year 2026. For the period, the company expects net sales of $313.5 million to $315.5 Million compared to previous guidance of $312 million to $314 Million as of January 6, 2026.
お知らせ • Mar 19AngioDynamics, Inc. to Report Q3, 2026 Results on Apr 02, 2026AngioDynamics, Inc. announced that they will report Q3, 2026 results Pre-Market on Apr 02, 2026
お知らせ • Jan 06+ 2 more updatesJim Clemmer Intends to Retire as President of AngioDynamics, Inc. During Fiscal year 2027AngioDynamics, Inc. announced that Jim Clemmer to retire during fiscal year 2027 as President and CEO upon appointment of successor; Board initiates comprehensive CEO search. The Company also announced that Mr. Clemmer has informed the Board of Directors of his intention to retire from the Company upon the appointment of a successor, which is anticipated to occur during fiscal 2027. The Board has established a search committee to conduct a comprehensive search, which will be assisted by a leading executive search firm, to identify the Company’s next CEO. Until his successor is appointed, Mr. Clemmer will continue as President and CEO, leading and overseeing the Company’s strategic and financial initiatives with a focus on revenue growth and profitability.
お知らせ • Dec 23AngioDynamics, Inc. to Report Q2, 2026 Results on Jan 06, 2026AngioDynamics, Inc. announced that they will report Q2, 2026 results Pre-Market on Jan 06, 2026
お知らせ • Oct 02AngioDynamics, Inc. Revises Earnings Guidance for the Full Fiscal Year 2026AngioDynamics, Inc. revised earnings guidance for the full fiscal year 2026. For the year, the company expects net sales to be between $308 million to $313 million against previous guidance of between $305 million to $310 million.
お知らせ • Sep 27AngioDynamics, Inc., Annual General Meeting, Nov 10, 2025AngioDynamics, Inc., Annual General Meeting, Nov 10, 2025.
お知らせ • Sep 18AngioDynamics, Inc. to Report Q1, 2026 Results on Oct 02, 2025AngioDynamics, Inc. announced that they will report Q1, 2026 results Pre-Market on Oct 02, 2025
お知らせ • Jul 29Angiodynamics, Inc. Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb IschemiaAngioDynamics, Inc. announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee (AMBITION BTK). AMBITION BTK is a prospective, multicenter, randomized controlled trial (RCT) designed to investigate the clinical safety and effectiveness of the Auryon Athe rectomy System combined with standard balloon angioplasty, compared to balloon angioplasty alone, in treating infrapopliteal lesions in patients with Critical Limb IschemIA (CLI).
お知らせ • Jul 15AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2026AngioDynamics, Inc. provided earnings guidance for the Fiscal Year 2026. For the year, the Company expected net sales to be in the range of $305 Million to $310 million.
お知らせ • Jul 07AngioDynamics, Inc. to Report Q4, 2025 Results on Jul 15, 2025AngioDynamics, Inc. announced that they will report Q4, 2025 results Pre-Market on Jul 15, 2025
お知らせ • Jun 24AngioDynamics Announces First Patient Enrolled in Recover-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary EmbolismAngioDynamics, Inc. announced the first patient has been enrolled in the RECOVER-AV clinical trial, a prospective, multi-center, multi-national, single-arm study evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute, intermediate-risk pulmonary embolism (PE). The study follows the United States Food and Drug Administration (FDA) 510(k) clearance of the AlphaVac F1885 System for the treatment of PE in the United States in April 2024 and its CE Mark approval in Europe in May 2024. The RECOVER-AV trial is designed to evaluate the safety and efficacy of the AlphaVac F 1885 System in support of its adoption in the Global market, as well as to assess long-term functional outcomes for patients following treatment. This study builds on the results of the Company's U.S.-based APEX-AV trial2, which demonstrated that the AlphaVac F18 85 System is safe and effective for use in intermediate-risk PE patients, with significant improvements in right ventricular function and reduction in clot burden. The AlphaVac F1885 system received CE Mark approval in May 2024 for the non-surgical removal of thrombi oremboli from the pulmonary arteries. The System is designed to support frontline treatment of PE and expand options for healthcare providers managing patients with life-threatening venous thromboembolism.
お知らせ • Apr 02AngioDynamics, Inc. Revises Earnings Guidance for the Fiscal Year 2025AngioDynamics, Inc. revised earnings guidance for the fiscal year 2025. The company now revises net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.
お知らせ • Mar 19AngioDynamics, Inc. to Report Q3, 2025 Results on Apr 02, 2025AngioDynamics, Inc. announced that they will report Q3, 2025 results Pre-Market on Apr 02, 2025
お知らせ • Jan 30AngioDynamics, Inc. Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb IschemiaAngioDynamics, Inc. announced the start of a Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee (AMBITION BTK). AMBITION BTK is a multicenter, randomized controlled trial (RCT) designed to evaluate the clinical outcomes of the Auryon Atherectomy System in combination with standard balloon angioplasty compared to standard balloon angioplasty alone for the treatment of infrapopliteal lesions in patients with critical limb ischemia. The trial will enroll up to 200 subjects across up to 30 hospital-based sites. Additionally, up to 1,500 subjects treated with the Auryon Atherectomy System at the same sites who do not meet the eligibility criteria of the RCT will be enrolled in a companion Registry. Lower extremity peripheral artery disease (PAD) affects more than 230 million adults worldwide and is associated with an increased risk of various adverse clinical outcomes. In its most severe form, critical limb ischemia patients are often treated with lower extremity amputation (LEA). The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR) and to date, it has been used to treat more than 100,000 patients in the United States and worldwide. AMBITION BTK builds upon the positive outcomes of a prior multicenter, prospective trial that evaluated the safety and effectiveness of the Auryon laser atherectomy system in treating BTK lesions in patients with limb ischemia. The earlier study successfully treated 61 complex, calcified lesions across four U.S. centers in 60 patients, achieving strong clinical outcomes with minimal complications. These results demonstrated the System's ability to safely and effectively address challenging BTK cases, leading to the development of the AMBITION BTK RCT and Registry. The technology underlying the Auryon Atherectomy System has been shown in clinical studies to be effective in treating lesions ranging from soft plaque to severely calcified. The System uses a 355nm wavelength laser platform, enabling the use of short UV laser pulses with targeted biological reactions that are effective in treating PAD while minimizing the risk of perforation and preserving the ability to vaporize lesions without thermal ablation. On February 1, 2025, the Company will host its inaugural Cardiovascular Scientific Forum (CVSF). The event will bring together leading physicians and thought leaders in the cardiovascular field to present groundbreaking research, discuss emerging clinical trends, and showcase advancements shaping the future of patient care, including the AMBITION BTK RCT and Registry.
お知らせ • Jan 14AngioDynamics, Inc. Announces Publication of Apex-Av Trial Results in JSCAIAngioDynamics, Inc. announced the publication of the results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI). The article, "Novel Mechanical Aspiration Thrombectomy in Patients with Acute Pulmonary Embolist: Results from the Prospective APEX-AV Trial," was published December 27, 2024. In December 2023, AngioDynamics announced the completion of patient enrollment in its APEX-AV trial, a single-arm Investigational Device Exemption study that enrolled 122 patients with confirmed acute, immediate-risk PE across 25 hospital-based sites in the United States to assess the AlphaVac F1885 System for the treatment of PE. In April 2024, the United States Food and Drug Administration (FDA) cleared the AlphaVac F18 85 System for the treatment of PE".
お知らせ • Dec 20AngioDynamics, Inc. to Report Q2, 2025 Results on Jan 08, 2025AngioDynamics, Inc. announced that they will report Q2, 2025 results Pre-Market on Jan 08, 2025
お知らせ • Dec 10AngioDynamics Receives FDA Clearance for the NanoKnife® System for Prostate Tissue AblationAngioDynamics, Inc. announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The Company received clearance for the NanoKnife System for prostate tissue ablation following the completion of the pivotal PRESERVE clinical study and submission of results to the FDA in September. The study evaluated the safety and effectiveness of the system for ablating prostate tissue in patients with intermediate-risk prostate cancer (PCa). Conducted in collaboration with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), PRESERVE enrolled 121 patients across 17 clinical sites. The PRESERVE clinical study met its primary effectiveness endpoint demonstrating the performance of the NanoKnife System for the ablation of prostate tissue in patients with intermediate-risk PCa. At 12-months post-procedure, 84.0% of men were free from in-field, clinically significant disease. In addition, the study demonstrated strong quality of life outcomes with short-term urinary continence being preserved (96.6% at baseline, 95.4% at 12-months) and the ability to maintain erections sufficient for intercourse only decreasing 9% compared to baseline (80.7% to 71.7%). The study’s results validated the robust safety and clinical efficacy profile of the NanoKnife System, reinforcing findings from more than 32 clinical studies performed around the world involving over 2,600 patients. Prostate cancer is the second most common cancer in men worldwide, with approximately 1.5 million new cases diagnosed annually. Many of these patients seek alternatives to radical procedures that can lead to significant, long-term urological side effects. The NanoKnife System is the first and only non-thermal, radiation-free, ablation technology designed to treat prostate tissue by using IRE technology, offering patients a minimally invasive option for prostate treatment. The NanoKnife System delivers an innovative alternative to conventional radical surgery or radiotherapy, which often results in significant dysfunction in urinary continence and erectile potency. With its non-thermal approach, the system is engineered to preserve vital structures inside and outside the prostate, offering patients improved outcomes, reduced recovery times, and enhanced quality of life.
お知らせ • Oct 25AngioDynamics, Inc. Announces the Launch of an International Multi-Center Prospective Registry StudyAngioDynamics, Inc. announced the launch of an international multi-center prospective registry study to assess the long term effects of treating men with unifocal intermediate-risk prostate cancer with the NanoKnife System in partnership with the University College London Hospital (UCLH). Approximately 40% of all diagnosed prostate cancer cases are classified as intermediate risk. In the first year after surgery, 36% of men report urinary leakage, and 95% are affected by erectile dysfunction (70% described as moderate/severe). The NanoKnife System delivers an innovative alternative to conventional radical surgery or radiotherapy, each of which often results in significant dysfunction in urinary continence and erectile potency. With its non-thermal approach, the NanoKnife system is engineered to preserve vital structures inside and outside the prostate, offering patients effective treatment of tumors, low complication rates, and minimal impact on quality of life. AngioDynamics is conducting the international multi-center prospective registry study in partnership with UCLH. UCLH is the largest center for robotic prostate surgery in the U.K. and a leading provider of focal therapy, radiotherapy, robotic surgery, and active surveillance treatment options for men with prostate cancer. Additionally, UCLH was the first facility in the National Health Service to use the NanoKnife System to treat prostate cancer, and provide standardized patient selection, treatment, and long-term follow-up. The study will enroll a minimum of 500 patients worldwide to confirm the multiple single-center published papers indicating that the NanoKnife System is safe and effective in the treatment of targeted tumors, and the prevention or delayed need for radical intervention in the preservation of patient quality of life. Complementing the ongoing Randomized Controlled Trial studies evaluating NanoKnife versus radical treatment, this investigator-initiated trial will closely monitor patients post-treatment, measuring critical quality of life metrics and tracking any necessary follow-up interventions. In addition to quality of life, the study will assess overall and prostate-specific mortality rates.
Recent Insider Transactions • Oct 10CEO, President & Director recently bought €110k worth of stockOn the 7th of October, James Clemmer bought around 20k shares on-market at roughly €5.49 per share. This transaction amounted to 4.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €172k worth in shares.
Breakeven Date Change • Oct 06No longer forecast to breakevenThe 3 analysts covering AngioDynamics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.20m in 2027. New consensus forecast suggests the company will make a loss of US$2.00m in 2027.
Reported Earnings • Oct 04First quarter 2025 earnings released: US$0.32 loss per share (vs US$1.15 profit in 1Q 2024)First quarter 2025 results: US$0.32 loss per share (down from US$1.15 profit in 1Q 2024). Revenue: US$67.5m (down 14% from 1Q 2024). Net loss: US$12.8m (down 128% from profit in 1Q 2024). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 03AngioDynamics, Inc. Provides Earnings Guidance for the Year 2025AngioDynamics, Inc. provided earnings guidance for the year 2025. For fiscal year 2025, the Company continues to expects net sales to be in the range of $282 to $288 million, representing growth of between 4.2% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.
New Risk • Sep 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).
お知らせ • Sep 27AngioDynamics, Inc., Annual General Meeting, Nov 12, 2024AngioDynamics, Inc., Annual General Meeting, Nov 12, 2024.
お知らせ • Sep 19AngioDynamics, Inc. to Report Q1, 2025 Results on Oct 03, 2024AngioDynamics, Inc. announced that they will report Q1, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 03, 2024
Reported Earnings • Jul 17Full year 2024 earnings released: US$4.59 loss per share (vs US$1.33 loss in FY 2023)Full year 2024 results: US$4.59 loss per share (further deteriorated from US$1.33 loss in FY 2023). Revenue: US$303.9m (down 10% from FY 2023). Net loss: US$184.3m (loss widened 252% from FY 2023). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
Breakeven Date Change • Jul 17Forecast to breakeven in 2027The 3 analysts covering AngioDynamics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$1.20m in 2027. Average annual earnings growth of 97% is required to achieve expected profit on schedule.
お知らせ • Jul 16+ 1 more updateAngioDynamics, Inc. (NasdaqGS:ANGO) announces an Equity Buyback for $15 million worth of its shares.AngioDynamics, Inc. (NasdaqGS:ANGO) announces a share repurchase program. Under the program, the company will repurchase up to $15 million worth of its shares.
お知らせ • Jul 09AngioDynamics, Inc. to Report Q4, 2024 Results on Jul 16, 2024AngioDynamics, Inc. announced that they will report Q4, 2024 results Pre-Market on Jul 16, 2024
New Risk • Jun 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.1m net loss in 3 years). Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).
New Risk • Apr 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.1m net loss in 3 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).
Recent Insider Transactions • Apr 09CEO, President & Director recently bought €62k worth of stockOn the 8th of April, James Clemmer bought around 10k shares on-market at roughly €6.17 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.
Reported Earnings • Apr 05Third quarter 2024 earnings released: US$4.73 loss per share (vs US$0.24 loss in 3Q 2023)Third quarter 2024 results: US$4.73 loss per share (further deteriorated from US$0.24 loss in 3Q 2023). Revenue: US$75.2m (down 6.9% from 3Q 2023). Net loss: US$190.4m (loss widened US$181.0m from 3Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Board Change • Apr 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Karen Licitra was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 05AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024AngioDynamics, Inc. provided sales guidance for the Fiscal Year 2024. For the year, the company expects net sales to be in the range of $270 million to $275 million which reflects the recent divestiture of the PICC and Midline businesses and discontinuance of the RadioFrequency ablation and Syntrax businesses, which accounted for approximately $50 million of the prior revenue guidance of $320 to $325 million. The Company expects gross margin to be approximately 52.0% to 54.0%.
お知らせ • Apr 04+ 1 more updateAngioDynamics, Inc. Reports Consolidated Goodwill Impairment for Third Quarter Ended February 29, 2024AngioDynamics, Inc. reported consolidated Goodwill impairment for third quarter ended February 29, 2024. For the quarter, the company reported Goodwill impairment of $159,476,000.
お知らせ • Apr 02Angiodynamics Announces Settlement of All Patent Litigation with C.R. Bard, IncAngioDynamics, Inc. announced that it has entered into a settlement agreement with Becton, Dickinson and Company (BD) to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD. Under the terms of the settlement, BD will grant a license to AngioDynamics under certain of BD’s port patents and AngioDynamics will grant BD a license under certain of AngioDynamics’ catheter patents. AngioDynamics will make a one-time lump sum payment to BD in the amount of $7 million, $3 million of which will be paid within five days and the balance of which will be payable of installments over the next 12 months. AngioDynamics will also make six minimum annual payments to BD of $2.5 million through February 2029, and potential additional payments if six percent (6%) of annual net sales of AngioDynamics’ port products exceed the minimum payment. The parties will participate in the pending appeal before the Federal Circuit of the case titled C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. v. AngioDynamics, Inc. (C.A. 15-00218–JFB; and CAFC appeal No. 23-2056) and a contingent payment of $3 million will be due from AngioDynamics to BD if the Federal Circuit reverses or vacates the District Court’s findings of invalidity with respect to the patent claims at issue the case. The agreement contains mutual covenants not to sue and releases. Neither party admitted any liability in connection with the settlement agreement. The agreement concludes a multi-year patent dispute between the parties.
お知らせ • Mar 20AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024AngioDynamics, Inc. announced that they will report Q3, 2024 results Pre-Market on Apr 04, 2024
お知らせ • Feb 16Angiodynamics, Inc. Announces Board ChangesAngioDynamics, Inc. announced that on February 8, 2024 the Board appointed Wesley Johnson as the new chair of the Audit Committee and Jan Stern Reed as the new chair of the Nominating, Compliance and Corporate Governance Committee. James Clemmer resigned from his position as a Class II director on the Board and was immediately re-appointed as a Class I director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders. The resignation and reappointment of Mr. Clemmer was effected solely for the purpose of rebalancing each class of directors to consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board, and for all other purposes, Mr. Clemmer’s service on the Board is deemed to have continued uninterrupted.
お知らせ • Jan 23+ 1 more updateAngiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial DiseaseAngioDynamics, Inc. announced that the United States Food and Drug Administration (FDA) has cleared the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in the treatment of Peripheral Arterial Disease (PAD). According to the American Heart Association, PAD affects 8.5 million Americans and 200 million people worldwide each year. Studies have shown that radial access is associated with a significantly lower risk of major bleeding and access site complications when compared to femoral access in the treatment of patients. The Auryon XL Catheter, available in 0.9 mm and 1.5 mm diameters, expands treatment access points in atherectomy procedures for PAD. Use of a general radial access catheter may reduce incidents of major bleeding, when compared to femoral access, by more than 70%. Additionally, it may eliminate the need for the use of femoral closure devices and allow for the treatment of bilateral disease in a single session, supporting improved patient mobility, earlier discharge and faster patient recovery times. Following FDA 510(k) clearance, AngioDynamics initiated a limited market release of the Auryon XL Catheter in the United States in January 2024 and expects to enter full market release in February 2024. The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR), and to date, it has been used to treat more than 50,000 patients7 in the United States. The technology underlying the Auryon Atherectomy System has been shown in clinical studies to be effective in treating lesions ranging from soft plaque to severely calcified5,6,8. The System uses a 355nm wavelength laser platform, enabling the use of short UV laser pulses with targeted biological reactions that are effective in treating PAD while minimizing the risk of perforation and preserving the ability to vaporize lesions without thermal ablation.
お知らせ • Jan 05+ 2 more updatesAngioDynamics, Inc. Announces Manufacturing Operations RestructuringAngioDynamics, Inc. announced that it is committed to shifting its manufacturing operations from a company-owned facility in upstate New York to a fully outsourced model over the next two years. This shift is expected to result in an approximate $15 million annualized reduction in expenses by fiscal year 2027.
お知らせ • Dec 08AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024AngioDynamics, Inc. announced that they will report Q2, 2024 results Pre-Market on Jan 05, 2024
お知らせ • Dec 07AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary EmbolismAngioDynamics, Inc. announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company's AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute intermediate-risk pulmonary embolism (PE). PERT represents the third-leading cause of cardiovascular mortality in the United States. APEX-AV is a single-arm Investigational Device Exemption study that enrolled 122 patients with confirmed acute, intermediate-risk PE across 25 hospital-based sites in the United States. The primary efficacy endpoint of the APEX-AV Study is the reduction in RV/LV ratio between baseline and 48 hours post-procedure. The primary safety endpoint is the rate of Major Adverse Events (MAEs), including device-related death and major bleeding within the first 48 hours. Patients will be followed for 30 days post-index procedure. AngioDynamics initiated the APEX-AV Study in partnership with the widely respected Pulmonary Embolism Response Team (PERT) Consortium™. The study is led by co-Principal Investigators William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™ and Mona Ranade, MD, Assistant Professor, Interventional Radiology, at the David Geffen School of Medicine at UCLA. Pulmonary embolism (PE) can be a life-threatening condition that affects around 900,000 people in the United States every year.2 In most cases, PE is caused by blood clots in the legs, called deep vein thrombosis, that travel to the lungs.2 Patients with submassive or intermediate-risk PE account for 35% to 55% of hospitalized patients with PE and have a mortality rate of 3 to 14%.
New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Large one-off items impacting financial results.
お知らせ • Oct 06Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024AngioDynamics, Inc. provided earning guidance for fiscal year 2024. The Company continues to expect its fiscal year 2024 net sales to be in the range of $328to $333 million and gross margin to be approximately 50% to 52%. For comparison, pro forma revenue, gross margin, and adjusted loss per share for FY23 when excluding the assets divested to Merit Medical were $306.3 million, 50.5%, and $0.43, respectively.
Reported Earnings • Oct 05First quarter 2024 earnings released: EPS: US$1.15 (vs US$0.33 loss in 1Q 2023)First quarter 2024 results: EPS: US$1.15 (up from US$0.33 loss in 1Q 2023). Revenue: US$78.7m (down 3.5% from 1Q 2023). Net income: US$45.9m (up US$58.9m from 1Q 2023). Profit margin: 58% (up from net loss in 1Q 2023). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Sep 29AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023, at 12:00 US Eastern Standard Time. Agenda: To consider and vote upon a proposal to elect four Class II directors, for a term of three years; to consider and vote upon a proposal to ratify the appointment of AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2024; to consider and vote upon a "Say-on-Pay" advisory vote on the approval of the compensation of AngioDynamics' named executive officers; to consider and vote upon a proposal to amend the AngioDynamics, Inc. 2020 Equity Incentive Plan to, among other things, increase the number of shares available for issuance; to hold a "Say-On-Pay Frequency" advisory vote on a non-binding resolution to determine the frequency our shareholders will be asked to approve the compensation of our named executive officers; and transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
お知らせ • Sep 13AngioDynamics, Inc. to Report Q1, 2024 Results on Oct 04, 2023AngioDynamics, Inc. announced that they will report Q1, 2024 results Pre-Market on Oct 04, 2023
お知らせ • Aug 17AngioDynamics, Inc. Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart VegetationAngioDynamics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company's AngioVac System for the proposed indications for use to include the non-surgical removal of vegetation from the right heart. The FDA Breakthrough Device designation is designed to help patients gain timely access to medical devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions for which no approved or cleared alternatives exist. Target vessels for the thrombus/embolus extraction include, but are not limited to, the iliofemoral vein, Inferior Vena Cava (IVC), Superior Vena Cava (SVC) and Right Heart. Under the Breakthrough Device designation, AngioDynamics will engage with the FDA to achieve this new expanded indication for the non-surgical removal from the right heart. The accelerated pathway expedites assessment and review processes of the AngioVac System and allows for more interactive and timely communication with the FDA, efficient and flexible clinical study design, FDA review team support, Agency senior management engagement and priority review.
お知らせ • Aug 04Angiodynamics, Inc. Completes Enrollment for Preserve Clinical StudyAngioDynamics, Inc. announced the completion of enrollment and final treatment in its Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population (PRESERVE). The PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC). Final patient enrollment in the study was initially announced during AngioDynamics’ Fiscal 2023 Fourth Quarter and Full-Year Financial Results conference call on July 12, 2023. Co-Principal Investigators leading the study are Jonathan Coleman, MD, Urologic Surgeon, Memorial Sloan Kettering Cancer Center, and Arvin George, MD, Urologic Surgeon, University of Michigan. The PRESERVE study will have its primary endpoint analysis at 12 months following treatment. In 2023, the American Cancer Society estimates that there will be about 288,300 new cases of prostate cancer and about 34,700 deaths from the disease in the U.S. It is estimated that 1 out of every 8 men will be diagnosed with prostate cancer during their lifetime, and prostate cancer is more likely to develop in older and non-Hispanic Black men. It is American men's second leading cause of death. The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted tissue, delivering precise treatment margins while preserving vital structures by retaining the structural integrity of the targeted tissue. The delivery of non-thermal energy allows for the preservation of the extra-cellular matrix, facilitating post-ablation histological and functional tissue regeneration. The PRESERVE study’s primary objectives are determining the NanoKnife System’s ablation effectiveness by measuring the negative in-field biopsy rate at 12 months and determining the NanoKnife System’s procedural and post-procedural safety profile by evaluating adverse event incidence, type and severity through 12 months. The study enrolled and treated 121 patients in 17 facilities across the United States.
お知らせ • Jul 25AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of DirectorsAngioDynamics, Inc. announced the appointment of Lorinda Burgess to the Company’s Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company’s Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. Ms. Burgess was most recently Chief Financial Officer and Vice President of Finance for the Americas Region at Medtronic, Inc., a Fortune 200 global medical device company with more than $30 billion in annual revenues. Prior to this role, Ms. Burgess also served as Vice President of Customer Care for the Americas and Western Europe at Medtronic, Inc. and Vice President of Finance for the Cardiovascular Group’s Sales and Marketing function. Ms. Burgess earned a Bachelor of Arts in Communication and Political Science from the University of Michigan and a Master’s in Business Administration from Ohio State University. Ms. Burgess is a member of the Board of Directors for Stepan Company. With Ms. Burgess’ appointment, AngioDynamics’ total number of directors will increase to nine members.
お知らせ • Jul 13AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024AngioDynamics, Inc. provided financial guidance for the fiscal year 2024. The company anticipates that fiscal year 2024 revenue will be in the range of $328 million to $333 million.
Reported Earnings • Jul 13Full year 2023 earnings released: US$1.33 loss per share (vs US$0.68 loss in FY 2022)Full year 2023 results: US$1.33 loss per share (further deteriorated from US$0.68 loss in FY 2022). Revenue: US$338.8m (up 7.1% from FY 2022). Net loss: US$52.4m (loss widened 98% from FY 2022). Revenue is forecast to grow 2.3% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Jun 21AngioDynamics, Inc. to Report Q4, 2023 Results on Jul 12, 2023AngioDynamics, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Jul 12, 2023
New Risk • Jun 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$37m Forecast net loss in 2 years: US$14m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$14m net loss in 2 years). Share price has been volatile over the past 3 months (7.2% average weekly change).
お知らせ • Jun 09Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million.Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million on June 8, 2023. The transaction was financed at closing through borrowings available under its long-term credit facility. The acquired assets generated approximately $33 million of revenue over the trailing twelve months ended May 31, 2023. The transaction will be dilutive to adjusted earnings per share and is expected to be slightly dilutive to corporate gross margins of AngioDynamics, Inc. Piper Sandler & Co. acted as lead financial advisor to Merit and Oppenheimer & Co. acted as a financial advisor to Merit. UBS Investment Bank acted as financial advisor to AngioDynamics, Inc. Parr Brown Gee & Loveless P.C. served as legal advisor to Merit. Cadwalader Wickersham & Taft served as legal advisor to AngioDynamics. Oppenheimer & Co. Inc. acted as financial advisor to Merit Medical Systems, Inc. Merit Medical Systems, Inc. (NasdaqGS:MMSI) completed the acquisition of Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) on June 8, 2023.
Breakeven Date Change • May 31Forecast to breakeven in 2026The 4 analysts covering AngioDynamics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$11.7m in 2026. Average annual earnings growth of 66% is required to achieve expected profit on schedule.
Reported Earnings • Mar 31Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.13 loss in 3Q 2022)Third quarter 2023 results: US$0.24 loss per share (further deteriorated from US$0.13 loss in 3Q 2022). Revenue: US$80.7m (up 9.1% from 3Q 2022). Net loss: US$9.49m (loss widened 91% from 3Q 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Feb 03Key Executive recently sold €55k worth of stockOn the 31st of January, David Helsel sold around 5k shares on-market at roughly €11.92 per share. This transaction amounted to 37% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. David has been a net seller over the last 12 months, reducing personal holdings by €240k.
お知らせ • Jan 06AngioDynamics, Inc. Reaffirms Revenue Guidance for Fiscal 2023AngioDynamics, Inc. reaffirms revenue Guidance for fiscal 2023. Management expects net sales to be in the range of $342 to $348 million.
Reported Earnings • Jan 06Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.21 loss in 2Q 2022)Second quarter 2023 results: US$0.21 loss per share (further deteriorated from US$0.21 loss in 2Q 2022). Revenue: US$85.4m (up 9.1% from 2Q 2022). Net loss: US$8.49m (loss widened 1.6% from 2Q 2022). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Breakeven Date Change • Jan 06The 4 analysts covering AngioDynamics previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 5.7% per year to 2024. The company is expected to make a profit of US$1.00m in 2025.
お知らせ • Dec 16AngioDynamics, Inc. to Report Q2, 2023 Results on Jan 05, 2023AngioDynamics, Inc. announced that they will report Q2, 2023 results at 9:30 AM, US Eastern Standard Time on Jan 05, 2023
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Jan Reed was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Nov 01AngioDynamics, Inc. Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary EmbolismAngioDynamics, Inc. announced the enrollment of the first patient in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV), a clinical study aimed at evaluating the efficacy and safety of the Company’s AlphaVac Multipurpose Mechanical Aspiration (MMA) F18 System in the treatment of acute intermediate-risk pulmonary embolism (PE). APEX-AV is a single-arm Investigational Device Exemption study enrolling patients with confirmed acute, intermediate-risk PE at up to 20 hospital-based sites in the United States. The primary efficacy endpoint of the APEX-AV Study is the reduction in RV/LV ratio between baseline and 48 hours post-procedure. The primary safety endpoint is the rate of Major Adverse Events (MAEs), including device-related death and major bleeding within the first 48 hours. Patients will be followed for 30 days post-index procedure. Pulmonary embolism can be a life-threatening condition and affects approximately 1 in 1,000 people in the U.S. every year. AngioDynamics initiated the APEX-AV Study in partnership with the widely respected Pulmonary Embolism Response Team (PERT) Consortium™. The Study is led by co-Principal Investigators William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and President, The PERT Consortium™ and Mona Ranade, MD, Assistant Professor, Interventional Radiology, at the David Geffen School of Medicine at UCLA.
Recent Insider Transactions • Oct 12CEO, President & Director recently bought €155k worth of stockOn the 10th of October, James Clemmer bought around 10k shares on-market at roughly €15.47 per share. This transaction amounted to 2.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €356k worth in shares.
Reported Earnings • Oct 07First quarter 2023 earnings released: US$0.33 loss per share (vs US$0.18 loss in 1Q 2022)First quarter 2023 results: US$0.33 loss per share (further deteriorated from US$0.18 loss in 1Q 2022). Revenue: US$81.5m (up 5.9% from 1Q 2022). Net loss: US$13.0m (loss widened 87% from 1Q 2022). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 18% per year.
お知らせ • Oct 07AngioDynamics, Inc. Reaffirms Earnings Guidance for the Year 2023AngioDynamics, Inc. reaffirms earnings guidance for the year 2023. Management is reaffirming its previously issued fiscal year 2023 guidance. Management expects net sales to be in the range of $342 to $348 million.
お知らせ • Sep 23AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022, at 12:00 US Eastern Standard Time. Agenda: To consider and vote upon a proposal to elect two class i directors, for a term of three years; to ratify the appointment of angiodynamics’ independent registered public accounting firm for the fiscal year ending may 31, 2023; to consider and vote upon a “say-on-pay” advisory vote on the approval of the compensation of angiodynamics’ named executive officers; to vote upon a proposal to approve an in increase the number of shares available for issuance under the angiodynamics, inc. 2020 equity incentive plan; to vote upon a proposal to approve an increase in the number of shares available for issuance under the angiodynamics, inc. employee stock purchase plan; and to transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
お知らせ • Sep 09AngioDynamics, Inc. to Report Q1, 2023 Results on Oct 06, 2022AngioDynamics, Inc. announced that they will report Q1, 2023 results Pre-Market on Oct 06, 2022
Recent Insider Transactions • Aug 03Key Executive recently sold €110k worth of stockOn the 29th of July, David Helsel sold around 5k shares on-market at roughly €22.00 per share. This was the largest sale by an insider in the last 3 months. David has been a seller over the last 12 months, reducing personal holdings by €269k.
Reported Earnings • Jul 13Full year 2022 earnings released: US$0.68 loss per share (vs US$0.82 loss in FY 2021)Full year 2022 results: US$0.68 loss per share (up from US$0.82 loss in FY 2021). Revenue: US$316.2m (up 8.7% from FY 2021). Net loss: US$26.5m (loss narrowed 16% from FY 2021). Over the next year, revenue is forecast to grow 8.2%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Breakeven Date Change • Jul 13Forecast to breakeven in 2025The 4 analysts covering AngioDynamics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 29% per year to 2024. The company is expected to make a profit of US$1.40m in 2025. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
お知らせ • Jul 13AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2023AngioDynamics, Inc. provided sales guidance for the fiscal year 2023. for the year, the company expects net sales to be in the range of $342 million to $348 million.
お知らせ • Jun 16AngioDynamics, Inc. to Report Q4, 2022 Results on Jul 12, 2022AngioDynamics, Inc. announced that they will report Q4, 2022 results Pre-Market on Jul 12, 2022
Recent Insider Transactions • May 03Key Executive recently sold €75k worth of stockOn the 28th of April, David Helsel sold around 4k shares on-market at roughly €21.32 per share. In the last 3 months, there was an even bigger sale from another insider worth €159k. David has been a seller over the last 12 months, reducing personal holdings by €159k.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Jan Reed was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Apr 08Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.092 loss in 3Q 2021)Third quarter 2022 results: US$0.13 loss per share (down from US$0.092 loss in 3Q 2021). Revenue: US$74.0m (up 3.9% from 3Q 2021). Net loss: US$4.96m (loss widened 40% from 3Q 2021). Over the next year, revenue is forecast to grow 8.4%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
お知らせ • Apr 08AngioDynamics, Inc. Provides Earnings Guidance for the Year 2022AngioDynamics, Inc. provided earnings guidance for the year 2022. For the year, the company net sales to be in the range of $310 to $315 million.
Recent Insider Transactions • Jan 19CEO, President & Director recently bought €201k worth of stockOn the 11th of January, James Clemmer bought around 10k shares on-market at roughly €20.10 per share. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.
お知らせ • Jan 07AngioDynamics, Inc. Reports Impairment for the Three Months Ended November 30, 2021AngioDynamics, Inc. reported impairment for the three months ended November 30, 2021. Fixed and intangible asset impairments and disposals was $67,000 against $90,000 a year ago.
Reported Earnings • Jan 07Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: US$0.21 loss per share (down from US$0.11 loss in 2Q 2021). Revenue: US$78.3m (up 7.6% from 2Q 2021). Net loss: US$8.35m (loss widened 96% from 2Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 7.2%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Jan 07AngioDynamics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022AngioDynamics, Inc. reiterated earnings guidance for the fiscal year 2022. The Company continues to expect its fiscal year 2022 net sales to be in the range of $310 to $315 million.
Recent Insider Transactions • Oct 23Key Executive recently sold €84k worth of stockOn the 20th of October, David Helsel sold around 3k shares on-market at roughly €24.02 per share. This was the largest sale by an insider in the last 3 months. David has been a seller over the last 12 months, reducing personal holdings by €154k.
Reported Earnings • Oct 03First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$77.0m (up 9.6% from 1Q 2021). Net loss: US$6.97m (loss widened 63% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Reported Earnings • Jul 16Full year 2021 earnings released: US$0.82 loss per share (vs US$4.39 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: US$291.0m (up 10% from FY 2020). Net loss: US$31.5m (loss narrowed 81% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.
